Evolus (EOLS) Cash & Current Investments (2018 - 2026)
Evolus' (EOLS) quarterly Cash & Current Investments came in at $49.8 million in Q1 2026, down 26.66% YoY from $67.9 million in Q1 2025, and down 7.49% on a QoQ basis from $53.8 million in Q4 2025.
Evolus (EOLS) Cash & Current Investments (2018 - 2026) Analysis & Trends
Evolus (EOLS) has 9 years of Cash & Current Investments data on file, last reported at $49.8 million in Q1 2026.
- Quarterly Cash & Current Investments fell 26.66% year-over-year to $49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.8 million (down 26.66% YoY) and the FY2025 annual result came in at $53.8 million, down 38.1% from the prior year.
- Cash & Current Investments slipped to $49.8 million in Q1 2026, from $53.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $106.7 million in Q1 2022 to a low of $31.5 million in Q1 2023.
- A 5-year average of $66.2 million and a median of $62.8 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 381.13% — and 2023, when it plunged 70.5%.
- Tracing EOLS's Cash & Current Investments over 5 years: stood at $53.9 million in 2022, then advanced by 16.53% to $62.8 million in 2023, then surged by 38.37% to $87.0 million in 2024, then plunged by 38.1% to $53.8 million in 2025, then retreated by 7.49% to $49.8 million in 2026.
- The last three Cash & Current Investments figures came in at $49.8 million (Q1 2026), $53.8 million (Q4 2025), and $43.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 164.00 Mn |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 45.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.17 Mn |
| Mar 31, 2026 | 49.79 Mn |
| Dec 31, 2025 | 53.83 Mn |
| Sep 30, 2025 | 43.52 Mn |
| Jun 30, 2025 | 61.74 Mn |
| Mar 31, 2025 | 67.89 Mn |
| Dec 31, 2024 | 86.95 Mn |
| Sep 30, 2024 | 85.04 Mn |
| Jun 30, 2024 | 93.67 Mn |
| Mar 31, 2024 | 96.96 Mn |
| Dec 31, 2023 | 62.84 Mn |
| Sep 30, 2023 | 38.69 Mn |
| Jun 30, 2023 | 41.71 Mn |
| Mar 31, 2023 | 31.46 Mn |
| Dec 31, 2022 | 53.92 Mn |
| Sep 30, 2022 | 65.57 Mn |
| Jun 30, 2022 | 84.48 Mn |
| Mar 31, 2022 | 106.67 Mn |
| Dec 31, 2021 | 146.26 Mn |
| Sep 30, 2021 | 107.80 Mn |